Lysergide tartrate (LSD) vs Psilocybin (COMP360)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline
Lysergide tartrate (LSD) · DT120
Developed by Definium Therapeutics
NCT06941844 · Phase 3 · active, not recruiting
Participants were randomized and the study was triple-blinded (participant, investigator, and outcomes assessor) against a placebo comparator, which minimizes bias from expectation effects common in psychedelic trials. The primary endpoint, change in a validated clinical depression severity scale (MADRS) at Week 6, showed a large and statistically significant improvement for the drug versus placebo (p<0.0001), meeting the pre-specified comparison in the favorable direction.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: September 2027 · NCT07592689 (registry estimate)
Reported efficacy
Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 (Baseline to Week 6): Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001. (met)
Result source: NCT06941844
Psilocybin (COMP360)
Developed by COMPASS Pathways
NCT05711940 · Phase 3 · active, not recruiting
This was a randomized, quadruple-blinded, active-comparator-controlled trial with a large sample size (572 participants) and a primary endpoint (MADRS depression score change) that is a validated, hard clinical measure of disease severity, not a lab biomarker. The primary comparison between the high dose and low-dose control arm reached statistical significance in the favorable direction (p<0.001), meeting the design's own pre-specified success criteria.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2029 · NCT06132178 (registry estimate)
Reported efficacy
COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score. (Week 6): COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001. (met)
Result source: NCT05711940
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lysergide tartrate (LSD) | Psilocybin (COMP360) |
|---|---|---|
| MADRS, change (acute) | —Trial running · NCT06941844 | -12 vs -6.8−5.2 vs placeboNCT03775200 |
| CGI-S, change (acute) | —Trial running · NCT06941844 | —Not posted · NCT05624268 |
| MADRS response | —Trial running · NCT06941844 | —Not posted · NCT05624268 |
| MADRS remission | —Trial running · NCT06941844 | —Not posted · NCT05624268 |
| Relapse (% of patients) | —Trial running · NCT06941844 | —Not posted · NCT05624268 |
MADRS, change (acute)
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
- Psilocybin (COMP360)
- -12 vs -6.8−5.2 vs placeboNCT03775200
CGI-S, change (acute)
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
- Psilocybin (COMP360)
- —Not posted · NCT05624268
MADRS response
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
- Psilocybin (COMP360)
- —Not posted · NCT05624268
MADRS remission
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
- Psilocybin (COMP360)
- —Not posted · NCT05624268
Relapse (% of patients)
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
- Psilocybin (COMP360)
- —Not posted · NCT05624268
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lysergide tartrate (LSD): 0 of 4 rows · Psilocybin (COMP360): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Psilocybin (COMP360) |
|---|---|
| Dropout rate | 0%25 mga NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result6.3%25 mg NCT03775200 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —25 mga NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result—25 mg NCT03775200 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%25 mga NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result6.3%25 mg NCT03775200 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 25 mga headache 31.6% blood pressure increased 15.8% depression 5.3% NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result25 mg headache 34.2% (placebo 25.3%) nausea 22.8% (placebo 5.1%) fatigue 15.2% (placebo 8.9%) NCT03775200 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Psilocybin (COMP360)
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lysergide tartrate (LSD)'s landscape · Psilocybin (COMP360)'s landscape